Banque Pictet & Cie SA Has $207,000 Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Banque Pictet & Cie SA cut its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 92.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,236 shares of the biotechnology company's stock after selling 40,750 shares during the quarter. Banque Pictet & Cie SA's holdings in Sarepta Therapeutics were worth $207,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. New York State Teachers Retirement System increased its stake in Sarepta Therapeutics by 3.3% during the 1st quarter. New York State Teachers Retirement System now owns 79,361 shares of the biotechnology company's stock worth $5,065,000 after purchasing an additional 2,512 shares in the last quarter. Exchange Traded Concepts LLC bought a new position in Sarepta Therapeutics in the first quarter valued at approximately $479,000. GAMMA Investing LLC lifted its stake in Sarepta Therapeutics by 4,682.8% in the first quarter. GAMMA Investing LLC now owns 40,845 shares of the biotechnology company's stock valued at $2,607,000 after buying an additional 39,991 shares in the last quarter. Proficio Capital Partners LLC bought a new position in Sarepta Therapeutics in the fourth quarter valued at approximately $3,829,000. Finally, Janney Montgomery Scott LLC bought a new position in Sarepta Therapeutics in the first quarter valued at approximately $821,000. 86.68% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on SRPT. Robert W. Baird cut their price target on shares of Sarepta Therapeutics from $60.00 to $30.00 and set an "outperform" rating on the stock in a research note on Tuesday, June 17th. Wells Fargo & Company cut their price target on shares of Sarepta Therapeutics from $100.00 to $75.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 17th. HC Wainwright reaffirmed a "sell" rating on shares of Sarepta Therapeutics in a research note on Wednesday, June 25th. JPMorgan Chase & Co. cut their price target on shares of Sarepta Therapeutics from $30.00 to $28.00 and set an "overweight" rating on the stock in a research note on Thursday. Finally, Royal Bank Of Canada cut their price target on shares of Sarepta Therapeutics from $87.00 to $58.00 and set a "sector perform" rating on the stock in a research note on Wednesday, May 7th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $58.54.

Sarepta Therapeutics Stock Down 4.7%

SRPT traded down $0.90 during trading on Friday, reaching $18.17. 3,075,372 shares of the stock were exchanged, compared to its average volume of 2,241,596. The stock has a market cap of $1.79 billion, a P/E ratio of -6.75 and a beta of 0.45. Sarepta Therapeutics, Inc. has a twelve month low of $16.88 and a twelve month high of $154.13. The stock's 50 day moving average price is $30.98 and its two-hundred day moving average price is $71.91. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.46 and a current ratio of 4.02.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The firm had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. Sarepta Therapeutics's quarterly revenue was up 80.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.73 earnings per share. Equities analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.